Supplementary File 1: STROBE checklist for manuscript 'Care of peripheral intravenous catheters in three hospitals in Spain: Mapping clinical outcomes and implementation of clinical practice guidelines' by Blanco-Mavillard et al.

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		This information is stated in the <i>Abstract</i> , at the start of the Methods section.
		(<i>b</i>) Provide in the abstract an informative and balanced summary of what was done and what was found
		This information is stated in the Methods and Results sections of the <i>Abstract</i> .
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
		<i>Background</i> section presents an overview of the question of peripheral intravenous catheter failure and the few systematic
		attempts to measure the adherence to recommendations regarding optimal PIVC care in European hospitals.
Objectives	3	State specific objectives, including any prespecified hypotheses
		This information is stated at the final of <i>Background</i> .
Methods		
Study design	4	Present key elements of study design early in the paper
		The key elements are presented at the beginning of the <i>Methods</i> section.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
		The context and locations are described early in the <i>Methods</i> section, under the subheading <i>Study design and participants</i> .

Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
		This information is given in the <i>Methods</i> section, under the subheading <i>Study design</i> and participants.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
		The main variables are described in the first paragraph of the subheading <i>Outcomes</i> .
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
		All variables and data compilation methods are described in the <i>Methods</i> section. The data compilation methods are given under the subheading <i>Outcomes</i> .
Bias	9	Describe any efforts to address potential sources of bias
		Efforts to reduce potential bias are described in the Methods section. These include training in relevant aspects of visual inspection of the PIVC care to homogenize responses of evaluations by external researchers to hospital.
Study size	10	Explain how the study size was arrived at
		Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
		This information is given under the subheading <i>Statistical analysis</i> .

Statistical methods	12	 (a) Describe all statistical methods, including those used to control for confounding This information is given under the subheading <i>Statistical analysis</i>. (b) Describe any methods used to examine subgroups and interactions This information is given under the subheading <i>Statistical analysis</i>. (c) Explain how missing data were addressed Not applicable, describe analytical methods taking account of sampling strategy Not applicable. (<i>e</i>) Describe any sensitivity analyses Not applicable.
D14 -		Not applicable.
Results	12	(a) Depart numbers of individuals at as 1
Participants	13	 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed This information is reported near the beginning of the <i>Results</i> section. (b) Give reasons for non-participation at each stage Not applicable. (c) Consider use of a flow diagram
Descriptive data	14	Not applicable.(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confoundersThe characteristics of the participants are described in the <i>Results</i> section and are detailed in Table 1 and 2.(b) Indicate number of participants with missing data for each variable of interest

		Not applicable.
Outcome data	15	Report numbers of outcome events or summary measures
		The comparative analysis of adherence by medical and surgical wards is detailed in Table 3.
Main results	16	 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included The description of the adherence to international recommendations of CPG includes a description of the sample (means and standard deviation) and bivariate analysis depending on nature of the distributions. (b) Report category boundaries when continuous were adjusted as a series of the distribution.
		 continuous variables were categorized The variables are presented in the same order in the results and in the tables of this report. (c) If relevant, consider translating estimates of relative risk into absolute risk
		for a meaningful time period Not applicable.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
		Not applicable.
Discussion		
Key results	18	Summarise key results with reference to study objectives
		The key results are highlighted early in the <i>Discussion</i> section.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias

		The study limitations are described under a specific sub-heading at the end of the <i>Discussion</i> section
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
		This information is provided in the <i>Discussion</i> section.
Generalisability	21	Discuss the generalisability (external validity) of the study results
		The external validity and the utility of the results are discussed towards the end of the <i>Discussion</i> section. The final paragraph in the same section offers an overview of the utility of our results.
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
		This information will be enclosed in the specific section for this purpose, in our submission, in accordance with the journal's indications. It is also given in the report, under the relevant subheading.

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.